Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
BTMD Stock Forecast 2026-2027
$2.32
Current Price
$111.02M
Market Cap
Buy 4
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to BTMD Price Targets
+139.7%
To High Target of $5.56
+94.0%
To Median Target of $4.50
+29.3%
To Low Target of $3.00
BTMD Price Momentum
-7.6%
1 Week Change
-16.5%
1 Month Change
-58.9%
1 Year Change
-10.8%
Year-to-Date Change
-61.5%
From 52W High of $6.03
+0.2%
From 52W Low of $2.32
📊 TOP ANALYST CALLS
Did BTMD Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Biote is one of their latest high-conviction picks.
Latest BTMD Stock Price Targets & Analyst Predictions
Based on our analysis of 6 Wall Street analysts, BTMD has a bullish consensus with a median price target of $4.50 (ranging from $3.00 to $5.56). The overall analyst rating is Strong Buy (9.2/10). Currently trading at $2.32, the median forecast implies a 94.0% upside. This outlook is supported by 4 Buy, 1 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
BTMD Analyst Ratings
4
Buy
1
Hold
0
Sell
BTMD Price Target Range
Low
$3.00
Average
$4.50
High
$5.56
Current: $2.32
Latest BTMD Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for BTMD.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Aug 7, 2025 | B. Riley Securities | Jeff Van Sinderen | Neutral | Downgrade | $4.00 |
| Mar 13, 2025 | Craig-Hallum | Alex Fuhrman | Buy | Maintains | $8.00 |
| Dec 16, 2024 | Craig-Hallum | Alex Fuhrman | Buy | Initiates | $12.00 |
| Mar 13, 2024 | Roth MKM | George Kelly | Buy | Reiterates | $9.00 |
| Feb 20, 2024 | B. Riley Securities | Jeff Van Sinderen | Buy | Initiates | $9.00 |
| Feb 1, 2024 | Jefferies | Kaumil Gajrawala | Buy | Initiates | $6.55 |
| Jan 18, 2024 | Truist Securities | Gregory Fraser | Buy | Maintains | $9.00 |
| Jan 18, 2024 | Roth MKM | George Kelly | Buy | Maintains | $7.00 |
| Aug 15, 2023 | TD Cowen | Brian Holland | Outperform | Maintains | $7.00 |
| Aug 14, 2023 | Roth MKM | George Kelly | Buy | Reiterates | $12.00 |
| Mar 30, 2023 | Roth MKM | George Kelly | Buy | Maintains | $11.00 |
| Sep 27, 2022 | Truist Securities | Gregory Fraser | Buy | Initiates | $10.00 |
| Jun 24, 2022 | Cowen & Co. | Brian Holland | Outperform | Initiates | $11.00 |
| Jun 23, 2022 | Roth Capital | George Kelly | Buy | Initiates | $9.00 |
Biote Corp. (BTMD) Competitors
The following stocks are similar to Biote based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Biote Corp. (BTMD) Financial Data
Biote Corp. has a market capitalization of $111.02M with a P/E ratio of 2.9x. The company generates $195.64M in trailing twelve-month revenue with a 14.7% profit margin.
Revenue growth is -6.7% quarter-over-quarter, while maintaining an operating margin of +18.1% and return on equity of -3.1%.
Valuation Metrics
Market Cap
$111.02M
Enterprise Value
$160.50M
P/E Ratio
2.9x
PEG Ratio
-0.1x
Price/Sales
0.6x
Growth & Margins
Revenue Growth (YoY)
-6.7%
Gross Margin
+71.8%
Operating Margin
+18.1%
Net Margin
+14.7%
EPS Growth
-23.5%
Financial Health
Cash/Price Ratio
+37.5%
Current Ratio
1.0x
Debt/Equity
-1.6x
ROE
-3.1%
ROA
+22.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Biote Corp. (BTMD) Business Model
About Biote Corp.
What They Do
Provides bioidentical hormone replacement therapy.
Business Model
Biote Corp. generates revenue by offering personalized hormone optimization therapies, primarily through innovative pellet therapy. The company not only sells these therapies but also educates healthcare providers to enhance the effectiveness and reach of its solutions, thereby creating a sustainable business model focused on patient outcomes.
Additional Information
Biote operates within the growing sectors of wellness, anti-aging, and preventive medicine, aligning with the trend towards personalized healthcare. The company's focus on innovative health solutions positions it well in the biotechnology and healthcare market, offering potential for growth as demand for such therapies increases.
Company Information
Sector
Healthcare
Industry
Medical Care Facilities
Employees
217
CEO
Mr. Bret Christensen
Country
United States
IPO Year
2022
Website
www.biote.comBiote Corp. (BTMD) Latest News & Analysis
Latest News
biote Corp. (BTMD) Q3 2025 Earnings Call Transcript
2 months ago
Quick Summary
Biote Corp. (BTMD) will hold its Q3 2025 earnings call on November 5, 2025, at 5 PM EST, featuring CEO Bret Christensen and CFO Robert Peterson.
Why It Matters
The earnings call provides key insights into Biote Corp's financial performance and strategic direction, which can influence stock prices and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Biote Reports Third Quarter 2025 Financial Results
2 months ago
Quick Summary
Biote (NASDAQ: BTMD) reported Q3 2025 financial results, focusing on growth from new providers, maximizing clinic value, and enhancing financial performance post-restructuring in May.
Why It Matters
Biote's restructuring and focus on growth and financial performance could enhance profitability and attract new investors, impacting stock value positively.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Biote Corp. (BTMD) reported quarterly earnings of $0.22 per share, exceeding the Zacks Consensus Estimate of $0.05, but down from $0.33 per share year-over-year.
Why It Matters
Biote Corp. exceeded earnings expectations, signaling strong performance, but a year-over-year decline in earnings may raise concerns about future growth.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Biote Corp. (Nasdaq: BTMD) will announce Q3 financial results on November 5, 2025, after market close, followed by a conference call at 5:00 p.m. ET.
Why It Matters
Biote Corp.'s upcoming financial results and conference call can signal performance trends and future guidance, influencing investor sentiment and stock valuation.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Biote Corp. maintains a Strong Buy rating amid restructuring. Growth prospects are supported by vertical integration and cost controls, despite reduced 2025 earnings guidance.
Why It Matters
Strong Buy rating signals confidence in Biote Corp.'s long-term growth despite short-term challenges, indicating potential for margin expansion and profitability, crucial for investment decisions.
Source: Seeking Alpha
Market Sentiment:
Positive
biote Corp. (BTMD) Q2 2025 Earnings Call Transcript
5 months ago
Quick Summary
Biote Corp. (NASDAQ: BTMD) will hold its Q2 2025 Earnings Conference Call on August 6, 2025, at 5:00 PM ET, featuring CEO Bret Christensen and CFO Robert C. Peterson.
Why It Matters
The earnings conference call provides insights into biote Corp.'s financial performance and strategic direction, influencing stock valuation and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Frequently Asked Questions About BTMD Stock
What is Biote Corp.'s (BTMD) stock forecast for 2026?
Based on our analysis of 6 Wall Street analysts, Biote Corp. (BTMD) has a median price target of $4.50. The highest price target is $5.56 and the lowest is $3.00.
Is BTMD stock a good investment in 2026?
According to current analyst ratings, BTMD has 4 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $2.32. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for BTMD stock?
Wall Street analysts predict BTMD stock could reach $4.50 in the next 12 months. This represents a 94.0% increase from the current price of $2.32. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Biote Corp.'s business model?
Biote Corp. generates revenue by offering personalized hormone optimization therapies, primarily through innovative pellet therapy. The company not only sells these therapies but also educates healthcare providers to enhance the effectiveness and reach of its solutions, thereby creating a sustainable business model focused on patient outcomes.
What is the highest forecasted price for BTMD Biote Corp.?
The highest price target for BTMD is $5.56 from at , which represents a 139.7% increase from the current price of $2.32.
What is the lowest forecasted price for BTMD Biote Corp.?
The lowest price target for BTMD is $3.00 from at , which represents a 29.3% increase from the current price of $2.32.
What is the overall BTMD consensus from analysts for Biote Corp.?
The overall analyst consensus for BTMD is bullish. Out of 6 Wall Street analysts, 4 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $4.50.
How accurate are BTMD stock price projections?
Stock price projections, including those for Biote Corp., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: January 18, 2026 8:48 PM UTC